UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Expanding the flexibility of base editing for high-throughput genetic screens in bacteria

Nucleic acids research, 2024-04, Vol.52 (7), p.4079

2024

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

The Lancet (British edition), 2012-05, Vol.379 (9829), p.1893-1901

2012

Link zum Volltext

Verfügbarkeit prüfen

Modulation of cardio-respiratory activity in mice via transcranial focused ultrasound

Ultrasound in medicine & biology, 2024-03, Vol.50 (3), p.332-340

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2307-2313

2012

Link zum Volltext

Verfügbarkeit prüfen

Cell- and Serum-Derived Proteins Act as DAMPs to Activate RAW 264.7 Macrophage-like Cells on Silicone Implants

ACS biomaterials science & engineering, 2024-03, Vol.10 (3), p.1418-1434

2024

Link zum Volltext

Verfügbarkeit prüfen

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Clinical cancer research, 2014-09, Vol.20 (17), p.4449-4458

2014

Link zum Volltext

Verfügbarkeit prüfen

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Nature medicine, 2024-01, Vol.30 (1), p.207-217

2024

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Nature medicine, 2024-05, Vol.30 (5), p.1500-1500

2024

Link zum Volltext

Verfügbarkeit prüfen

Cancer immunotherapy: Checkpoint inhibitors, adoptive cell therapy, and beyond

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S12-S12

Blackman, Samuel C.

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

Journal of pharmaceutical sciences, 2013-09, Vol.102 (9), p.3100-3109

2013

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation

Drug metabolism and disposition, 2013-12, Vol.41 (12), p.2215

2013

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib

Journal of clinical pharmacology, 2015-04, Vol.55 (4), p.392-400

2015

Link zum Volltext

Verfügbarkeit prüfen

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion

JCO precision oncology, 2023-07, Vol.7, p.e2300065

2023

Link zum Volltext

Verfügbarkeit prüfen

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors

Journal of clinical pharmacology, 2013-09, Vol.53 (9), p.955-961

2013

Link zum Volltext

Verfügbarkeit prüfen

A Dempster-Shafer approach to multi-sensor track association

2016 IEEE Aerospace Conference, 2016, p.1-9

2016

Link zum Volltext

Verfügbarkeit prüfen

Forehead swelling caused by Pott's puffy tumor in a 9‐year‐old boy with sinusitis

Pediatrics international, 2005-12, Vol.47 (6), p.704-707

2005

Link zum Volltext

Verfügbarkeit prüfen

BIOM-37. INITIAL RADIOGRAPHIC ASSESSMENT OF ADC VALUES IN PEDIATRIC PATIENTS TREATED WITH DAY101 FOR RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS (LGGs) HARBORING MEK/ERK PATHWAY ALTERATIONS

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii9-ii9

2020

Link zum Volltext

Verfügbarkeit prüfen

Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent

Journal of pediatric hematology/oncology, 2009-11, Vol.31 (11), p.861-864

2009

Link zum Volltext

Verfügbarkeit prüfen

Chandipura Viral Glycoprotein (CNV-G) Promotes Gectosome Generation and Enables Delivery of Intracellular Therapeutics

Molecular therapy, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

IMG-05. INITIAL RADIOGRAPHIC ASSESSMENT OF DWI AND ADC VALUES IN CHILDREN AND YOUNG ADULTS TREATED WITH DAY101 (TAK-580) FOR RECURRENT LOW-GRADE GLIOMAS (LGG) HARBORING MAPK ALTERATIONS

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii355-iii356

2020

Link zum Volltext

Verfügbarkeit prüfen

Prenatal Diagnosis and Subsequent Treatment of an Intermediate-Risk Paraspinal Neuroblastoma: Case Report and Review of the Literature

Fetal diagnosis and therapy, 2008-08, Vol.24 (2), p.119-125

2008

Link zum Volltext

Verfügbarkeit prüfen

CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii77-vii78

2022

Link zum Volltext

Verfügbarkeit prüfen

Elucidating the Source of DAMPs in Macrophage Activation in the Foreign Body Response to Silicone Implants

Blackman, Samuel Austin

2022

Link zum Volltext
ProQuest

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF -altered recurrent or progressive low-grade glioma or advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS10062-TPS10062

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(95)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(113)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(47)
Humans
(33)
Female
(19)
Male
(19)
Adult
(18)
Middle Aged
(11)
Pediatrics
(11)
Biological And Medical Sciences
(10)
Oncology
(10)
Medical Sciences
(9)
Animals
(8)
Biology
(8)
Life Sciences & Biomedicine - Other Topics
(8)
Physical Sciences
(8)
Aged
(7)
Technology
(7)
Child
(6)
Pharmacology & Pharmacy
(6)
Proto-Oncogene Proteins B-Raf - Genetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Expanding the flexibility of base editing for high-throughput genetic screens in bacteria

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Modulation of cardio-respiratory activity in mice via transcranial focused ultrasound

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Cell- and Serum-Derived Proteins Act as DAMPs to Activate RAW 264.7 Macrophage-like Cells on Silicone Implants

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Cancer immunotherapy: Checkpoint inhibitors, adoptive cell therapy, and beyond

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

A Dempster-Shafer approach to multi-sensor track association

Forehead swelling caused by Pott's puffy tumor in a 9‐year‐old boy with sinusitis

BIOM-37. INITIAL RADIOGRAPHIC ASSESSMENT OF ADC VALUES IN PEDIATRIC PATIENTS TREATED WITH DAY101 FOR RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS (LGGs) HARBORING MEK/ERK PATHWAY ALTERATIONS

Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent

Chandipura Viral Glycoprotein (CNV-G) Promotes Gectosome Generation and Enables Delivery of Intracellular Therapeutics

IMG-05. INITIAL RADIOGRAPHIC ASSESSMENT OF DWI AND ADC VALUES IN CHILDREN AND YOUNG ADULTS TREATED WITH DAY101 (TAK-580) FOR RECURRENT LOW-GRADE GLIOMAS (LGG) HARBORING MAPK ALTERATIONS

Prenatal Diagnosis and Subsequent Treatment of an Intermediate-Risk Paraspinal Neuroblastoma: Case Report and Review of the Literature

CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

Elucidating the Source of DAMPs in Macrophage Activation in the Foreign Body Response to Silicone Implants

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF -altered recurrent or progressive low-grade glioma or advanced solid tumors

Suchergebnisse filtern